Serial No.: 10/764,016 Attorney Docket No. 01235-19045 (23625.CON)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: David Fikstad

SERIAL NO.: 10/764,016

FILING DATE: 01/23/2004

FOR: PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED

SOLUBILIZER RELEASE

ART UNIT: 1614

EXAMINER: Leslie Royds

DOCKET NO.: 01235-19045 (23625.CON)

THORPE NORTH & WESTERN, LLP 8180 South 700 East, Suite 200 Sandy, Utah 84070

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116 AND STATEMENT OF SUBSTANCE OF THE INVERVIEW UNDER 1.33(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the final office action mailed April 20, 2006, please enter this amendment, and reconsider this application in view of the remarks provided below. A Request for Continued Examination (RCE), a petition for a two month extension of time and the appropriate fees therefore are enclosed herewith.

INTERVIEW SUMMARY

A telephonic interview was held on August 3, 2006 with Examiners Leslie Royds and Ardin Marschel and Applicants' representatives Mr. David Osborne and Dr. Todd Alder. During the interview, the common ownership between the asserted '192 reference and the present application was discussed. Additionally, potential claim amendments in connection with inventorship amendments were discussed. Finally, the possibility of filing an RCE with specific claim amendments introducing certain solubilizer and release modulator combinations was discussed.